[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100580554":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":23,"responsibleParty":39,"collaborators":41,"id":45,"slug":7,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":7,"eligibilityCriteria":50,"healthyVolunteers":46,"sex":51,"minAge":52,"maxAge":7,"enrollmentInfo":53,"targetDuration":56,"studyType":57,"phases":7,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":26,"whyStopped":7,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"National Taiwan University Hospital","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DIAGNOSTIC_TEST","blood draw","Plasma samples will be collected in NTU Hospital or NTUCC. ChLIA kits and all other reagents will be provided by Volition. ChLIA analysis of samples will be performed by a Volition designated laboratory in Taiwan( NTU Centres of Genomic and Precision Medicine).",[14,19],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Pei-Hsing Chen, MD","CONTACT","886-2-2312-3456 Ext. 53422","chenph@ntu.edu.tw",{"name":20,"role":16,"phone":21,"phoneExt":7,"email":22},"Jin-Shing Chen, M.D., Ph.D.","86-2-2322-0322","chenjs@ntu.edu.tw",[24],{"facility":25,"status":26,"city":27,"state":7,"zip":7,"country":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"National Taiwan University","RECRUITING","Taipei","Taiwan",{"type":30,"coordinates":31},"Point",[32,33],121.52639,25.05306,{"lat":33,"lon":32},[36],{"name":37,"role":16,"phone":38,"phoneExt":7,"email":18},"Dobbie Pei-Hsing Chen, MD","886-2-23123456",{"type":40,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[42],{"name":43,"class":44},"Volition Diagnostics UK Ltd","UNKNOWN","100580554",false,"NCT06838806","Epigenetic Nucleosomes in Plasma for Pulmonary Nodule Differentiation","Differentiating Benign and Malignant Pulmonary Nodules Using Epigenetically Modified Nucleosomes in Plasma","Inclusion Criteria:\n\n* Aged 20 or older\n* Underwent a low-dose chest CT scan or a standard chest CT scan, showing lung nodules ≥ 6mm\n* Individuals understand the content of the consent form and are willing to participate in this study.\n* The lung nodule is assessed by a physician as high-risk, requiring thoracic surgery or biopsy for diagnosis\n\nExclusion Criteria:\n\n* Pregnant women\n* Individuals without capacity for consent, unable to understand the content of the consent form, or unwilling to participate in this study\n* Assessed by a physician as unsuitable for thoracic surgery or biopsy for diagnosis","ALL","20 Years",{"count":54,"type":55},500,"ESTIMATED","6 Months","OBSERVATIONAL","Investigators aim to evaluate the diagnostic accuracy of the Nu.Q blood test for lung cancer in the Taiwanese population and compare its diagnostic performance with low-dose computed tomography (LDCT) or computed tomography (CT). Additionally, investigators will investigate the potential role of Nu.Q in lung cancer prevention and its impact on survival outcomes.\n\nStudy Method:\n\nInvestigators plan to collect 20 mL of blood samples from individuals undergoing chest LDCT\u002FCT, isolate plasma for Nu.Q™ analysis, and compare the results with corresponding lung cancer pathology findings. The estimated sample size is 500 participants.",[60],"Lung Nodule",[62,63],"liquid biopsy","epigenetic","2025-11-16",{"date":66,"type":67},"2025-11-19","ACTUAL",{"date":69,"type":67},"2025-03-11",{"date":71,"type":55},"2026-03-31",{"name":5,"class":6},1]